Evidence map›Paper›PMID 30232178›Full record

ArticleJournal of virology2018

Molecular Characterization of the Viroporin Function of Foot-and-Mouth Disease Virus Nonstructural Protein 2B.

D P Gladue, E Largo, I de la Arada, V M Aguilella, A Alcaraz, J L R Arrondo, L G Holinka, E Brocchi, E Ramirez-Medina, E A Vuono and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

D P Gladue *Plum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA.
E Largo *Biofisika Institute (CSIC-UPV/EHU), University of the Basque Country, Bilbao, Spain.
I de la AradaBiofisika Institute (CSIC-UPV/EHU), University of the Basque Country, Bilbao, Spain.
V M AguilellaLaboratory of Molecular Biophysics, Department of Physics, University Jaume I, Castellón de la Plana, Spain.
A AlcarazLaboratory of Molecular Biophysics, Department of Physics, University Jaume I, Castellón de la Plana, Spain.
J L R ArrondoBiofisika Institute (CSIC-UPV/EHU), University of the Basque Country, Bilbao, Spain.
L G HolinkaPlum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA.
E BrocchiIstituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy.
E Ramirez-MedinaPlum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA.
E A VuonoPlum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA.
K A BerggrenPlum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA.
C CarrilloPlum Island Animal Disease Center, APHIS, USDA, Greenport, New York, USA.
J L NievaBiofisika Institute (CSIC-UPV/EHU), University of the Basque Country, Bilbao, Spain.
M V BorcaPlum Island Animal Disease Center, ARS, USDA, Greenport, New York, USA manuel.borca@ars.usda.gov.
Plum Island Animal Disease Center · USBiofisika · ESUniversitat Jaume I · ESIstituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini" · ITUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonstructural protein 2B of foot-and-mouth disease (FMD) virus (FMDV) is comprised of a small, hydrophobic, 154-amino-acid protein. Structure-function analyses demonstrated that FMDV 2B is an ion channel-forming protein. Infrared spectroscopy measurements using partially overlapping peptides that spanned regions between amino acids 28 and 147 demonstrated the adoption of helical conformations in two putative transmembrane regions between residues 60 and 78 and between residues 119 and 147 and a third transmembrane region between residues 79 and 106, adopting a mainly extended structure. Using synthetic peptides, ion channel activity measurements in planar lipid bilayers and imaging of single giant unilamellar vesicles (GUVs) revealed the existence of two sequences endowed with membrane-porating activity: one spanning FMDV 2B residues 55 to 82 and the other spanning the C-terminal region of 2B from residues 99 to 147. Mapping the latter sequence identified residues 119 to 147 as being responsible for the activity. Experiments to assess the degree of insertion of the synthetic peptides in bilayers and the inclination angle adopted by each peptide regarding the membrane plane normal confirm that residues 55 to 82 and 119 to 147 of 2B actively insert as transmembrane helices. Using reverse genetics, a panel of 13 FMD recombinant mutant viruses was designed, which harbored nonconservative as well as alanine substitutions in critical amino acid residues in the area between amino acid residues 28 and 147. Alterations to any of these structures interfered with pore channel activity and the capacity of the protein to permeabilize the endoplasmic reticulum (ER) to calcium and were lethal for virus replication. Thus, FMDV 2B emerges as the first member of the viroporin family containing two distinct pore domains.

Indexed as

Cell Membrane PermeabilityVirus ReplicationAmino Acid SequenceAnimalsCells, CulturedCricetinaeFoot-and-Mouth DiseaseFoot-and-Mouth Disease VirusIon TransportLipid BilayersMutationPeptide FragmentsProtein DomainsSequence HomologyViral Nonstructural ProteinsLipid BilayersPeptide FragmentsViral Nonstructural Proteins2BFMDFMDVfoot-and-mouth diseaseviroporin

Identifiers

PMID30232178
PMCPMC6232471
OpenAlexW2890330593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.